Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention

The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.

Inclusion Criteria:

• Age≥75 years old;
• Treated with PCI (limited to stent implantation) ;
• Survivors and treated with DAPT (aspirin [100 mg once daily], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist [clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)]) at discharge;

Exclusion Criteria:

• Coronary artery bypass graft (CABG) or only drug conservative treatment during hospitalization;
• Concurrent use of oral anticoagulants;
• Inability to tolerate long-term antiplatelet therapy, such as active bleeding and a bleeding tendency;
• Acute infectious diseases;
• Cognitive impairment;
• Declined re-examination.